The Opioid Industry Documents Archive (OIDA), a project of UCSF, and Johns Hopkins University, today released more than 114,000 documents related to McKinsey & Company's work as a management consulting firm for the opioid industry.
A significant proportion of bacterial sexually transmitted infections – gonorrhea, chlamydia, or syphilis – were prevented with a dose of doxycycline after unprotected sex, according to preliminary results of a clinical trial.
In a study, UCSF neurologist William Seeley, MD, and colleagues identified two key moments in the natural history of Alzheimer’s, pointing to a window of opportunity for treatment with amyloid-lowering drugs.
UCSF researchers successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types.
A UCSF-led study found a new drug for ALS that shows to slow or temporarily stall the progression of ALS in a select group of patients, with three times as many patients' disease slowing compared to those who received a placebo.
Hoping to discover a new approach to treating depression, UCSF researchers looked at mitochondrial proteins and found that people with untreated depression have significantly lower levels of these proteins. New hypotheses emerge about the relationship between depression and the function of the brain’s energy-hungry neurons.
Researchers at UCSF’s Quantitative Biosciences Institute (QBI) have observed how molecular switches regulate many different biological processes simultaneously. Their findings may shed light on how disease mutations operate, offering new ways to target malfunctioning switches and prevent illness.
UCSF researchers have leveraged two new molecules, one of which is currently in clinical oncology trials, to devise a dual-drug therapy for alcohol use disorder (AUD), without the side effects or complications associated with current treatment regimens.